[Adverse side effects caused by topically applied antiviral agents in herpetic keratitis]
- PMID: 2480457
[Adverse side effects caused by topically applied antiviral agents in herpetic keratitis]
Abstract
The present paper reviews the adverse side effects caused by topically applied antiviral agents in herpetic keratitis. The effective treatment of herpetic keratitis with IDU, a chemotherapeutic agent, was first reported in 1962. After its introduction into ophthalmic therapy for herpetic keratitis, drops of IDU were administered every hour by day combined with ointment every two hours by night. The therapy often continued for months or in some cases, even more than one year. Numerous reports on its side effects have appeared. The side effects can be classified into two categories. The first category is allergic contact blepharodermatitis, a type IV delayed hypersensitivity reaction. Its occurrence is difficult to foresee. This category I side effect rarely results in the destruction of the ocular tissues. The second category of side effects is a drug-induced toxic side effect resulting in punctate epithelial keratitis, papillary conjunctivitis or follicular hypertrophy and lacrimal punctal obstruction. After withdrawal of IDU, these ill effects usually subside soon. When IDU is further continued, the destructive change of the tissues will ensue. Conjunctival cicatrization, symblepharon, corneal neovascularization, cicatrization and irreversible punctal occlusion have been reported in cases with prolonged IDU treatment. In addition to IDU for therapy of herpetic keratitis, we are fortunate to have F3T, Ara-A and acyclovir. They show no cross sensitivity reaction nor any cross toxic reaction to each other. However, if administered more than several times daily and continued for a prolonged period of time, these antiviral agents, like IDU, can also result in reversible side effects and, further, irreversible tissue destruction. Conjunctival cicatrization and permanent punctal occlusion caused by prolonged administration of F3T have been reported. Prompt recognition of the untoward reactions and withdrawal of the antiviral agent will result in the subsidence of the toxic reaction changes and prevent the eye from irreversible destruction. The recognition, prevention and management of the untoward side effects also are discussed.
Similar articles
-
Side effects in the treatment of herpetic keratitis.Curr Eye Res. 1987 Jan;6(1):237-9. doi: 10.3109/02713688709020097. Curr Eye Res. 1987. PMID: 3103984
-
The treatment of herpes simplex virus epithelial keratitis.Trans Am Ophthalmol Soc. 2000;98:505-32. Trans Am Ophthalmol Soc. 2000. PMID: 11190039 Free PMC article.
-
Ara-A and IDU therapy of human superficial herpetic keratitis.Invest Ophthalmol. 1975 Oct;14(10):762-3. Invest Ophthalmol. 1975. PMID: 1102484 Clinical Trial.
-
Treatment of herpetic keratitis.Doc Ophthalmol. 1977 Sep 30;44(1):23-33. doi: 10.1007/BF00171452. Doc Ophthalmol. 1977. PMID: 411644
-
Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.Drugs. 1982 May;23(5):329-53. doi: 10.2165/00003495-198223050-00001. Drugs. 1982. PMID: 6284470 Review.
Cited by
-
Herpes simplex virus 1 targets IRF7 via ICP0 to limit type I IFN induction.Sci Rep. 2020 Dec 17;10(1):22216. doi: 10.1038/s41598-020-77725-4. Sci Rep. 2020. PMID: 33335135 Free PMC article.
-
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002898. doi: 10.1002/14651858.CD002898.pub4. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2015 Jan 09;1:CD002898. doi: 10.1002/14651858.CD002898.pub5. PMID: 21154352 Free PMC article. Updated.
-
Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.Cochrane Database Syst Rev. 2015 Jan 9;1(1):CD002898. doi: 10.1002/14651858.CD002898.pub5. Cochrane Database Syst Rev. 2015. PMID: 25879115 Free PMC article.